Aakanksha Khandelwal, Ph.D.
Affiliations: | 2007 | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Pharmacology, OncologyGoogle:
"Aakanksha Khandelwal"Parents
Sign in to add mentor| Vincent C. Njar | grad student | 2007 | University of Maryland Medical School | |
| (Retinoids and retinoic acid metabolism blocking agents in combination with histone deacetylase inhibitors for prostate cancer therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Godbole AM, Ramalingam S, Ramamurthy VP, et al. (2014) VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. European Journal of Pharmacology. 734: 98-104 |
| Vasaitis T, Belosay A, Schayowitz A, et al. (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics. 7: 2348-57 |
| Gediya LK, Khandelwal A, Patel J, et al. (2008) Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. Journal of Medicinal Chemistry. 51: 3895-904 |
| Khandelwal A, Gediya L, Njar V. (2008) MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. British Journal of Cancer. 98: 1234-43 |
| Purushottamachar P, Khandelwal A, Vasaitis TS, et al. (2008) Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry. 16: 3519-29 |
| Gediya LK, Belosay A, Khandelwal A, et al. (2008) Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorganic & Medicinal Chemistry. 16: 3352-60 |
| Gediya L, Purushottamachar P, Khandelwal A, et al. (2008) 27 INVITED Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/ CYP26 inhibitors for breast cancer therapy European Journal of Cancer Supplements. 6: 12 |
| Patel JB, Mehta J, Belosay A, et al. (2007) Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. British Journal of Cancer. 96: 1204-15 |
| Purushottamachar P, Khandelwal A, Chopra P, et al. (2007) First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 15: 3413-21 |
| Patel JB, Khandelwal A, Chopra P, et al. (2007) Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemotherapy and Pharmacology. 60: 899-905 |